Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate (<scp>OKV</scp>‐1001): A pilot open‐label, single‐arm multicentric clinical trial

Modified-release mycophenolate (OKV-1001) may represent a promising alternative treatment option for dogs with moderate-to-severe AD. The safety and efficacy profile of OKV-1001 will need to be established in larger, placebo-controlled clinical trials.

Authors

Michael Klotsman (ORCID: https://orcid.org/0000-0002-3200-8053)
Danielle Wyatt
Wayne H. Anderson (ORCID: https://orcid.org/0000-0003-0472-6856)
Domenico Santoro (ORCID: https://orcid.org/0000-0002-4893-4289)
Natalie Theus
Tom Lewis

Institutions

University of North Carolina at Chapel Hill (US)
University of Florida (US)
Sunesis (United States) (US)

Publication Details

Journal: Veterinary Dermatology
Published: 2024-08-12
DOI: https://doi.org/10.1111/vde.13283
Citations: 2
Primary Topic: Dermatology and Skin Diseases
Type: article
Field-Weighted Citation Impact: 1.07

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate (OKV‐1001): A pilot open‐label, single‐arm multicentric clinical trial

Michael Klotsman, Danielle Wyatt, Wayne H. Anderson, Domenico Santoro et al.

Aug 12, 2024

2 citations

Veterinary Dermatology

Dermatology and Skin Diseases

1.07

article

Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate (OKV‐1001): A pilot open‐label, single‐arm multicentric clinical trial

Michael Klotsman, Danielle Wyatt, Wayne H. Anderson, Domenico Santoro, Natalie Theus, Tom Lewis

August 12, 2024article en

2 citations

Abstract

Modified-release mycophenolate (OKV-1001) may represent a promising alternative treatment option for dogs with moderate-to-severe AD. The safety and efficacy profile of OKV-1001 will need to be established in larger, placebo-controlled clinical trials.

Veterinary DermatologyVol. 35(6)

University of North Carolina at Chapel Hill (US), University of Florida (US), Sunesis (United States) (US)

Good health and well-being

Openalex Percentile: Top 21%

Dermatology and Skin Diseases

1.07

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Treatment of moderate‐to‐severe canine atopic dermatitis with modified‐release mycophenolate (<scp>OKV</scp>‐1001): A pilot open‐label, single‐arm multicentric clinical trial — Michael Klotsman, Danielle Wyatt, et al. · Veterinary Dermatology (2024) | TGRS Research Map | TGRS